Sita Andarini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sita Andarini has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
Jamal Zaini
Division of Thoracic Oncology, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Indonesia, Persahabatan Hospital, Jakarta, Indonesia
5 shared publicationsToshihiro Nukiwa
Department of Respiratory Oncology and Molecular Medicine, Institute of Development, Aging and Cancer, 2Department of Microbiology and Immunology, Graduate School of Medicine, and 3Division of Microbiology and Immunology, Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Tohoku University, Sendai, Japan. 4Laboratory for Immune Regulation, RIKEN Research Center for Allergy and Immunology, Yokohama, Japan
5 shared publications- Jamal Zaini
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Persahabatan Hospital National Respiratory Center, Jakarta, Indonesia
4 shared publications - Toshiaki Kikuchi
Department of Respiratory Oncology and Molecular Medicine, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan
4 shared publications Yasuo Saijo
Department of Respiratory Oncology and Molecular Medicine, Institute of Development, Aging and Cancer, 2Department of Microbiology and Immunology, Graduate School of Medicine, and 3Division of Microbiology and Immunology, Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Tohoku University, Sendai, Japan. 4Laboratory for Immune Regulation, RIKEN Research Center for Allergy and Immunology, Yokohama, Japan
4 shared publicationsAchmad Hudoyo
Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Indonesia, Persahabatan Hospital, Jakarta, Indonesia
3 shared publications
Latest Publications
- Open Access
- 2 December 2025
- Published by Persahabatan Hospital in Persahabatan Respirology Journal
- Vol. 1 (1) , 23
Multidiscipline in Respiratory Care
Background: Respiratory diseases continue to be one of the significant burdens of morbidityand mortality in the world, with tuberculosis, pneumonia, COPD, and lung cancer featuringamong the most important causes. These are complex conditions with comprehensivemedical, functional, nutritional, medical rehabilitation, and psychosocial managementrequirements. This narrative review outlines the rationale, structure, and clinical impact ofmultidisciplinary respiratory care and emphasizes how such care may improve outcomes,coordination, and patient satisfaction. Discussion: A multidisciplinary team that includes respirologists, thoracic surgeons, nurses,nutritionists, and palliative specialists can allow for integrated patient-centered management,with enhancement in diagnostic accuracy, treatment efficacy, and continuity of care.Evidence shows reductions in hospital readmissions, improved survival, and better quality oflife with these approaches. Persahabatan National Respiratory Hospital is an example of thisapproach through structured multidisciplinary teams in lung cancer, interstitial lung disease,and tuberculosis. Despite resource and system integration challenges, there is a promisingoutlook for strengthening digital coordination, leadership support, and national policyalignment. Conclusion: Multidisciplinary respiratory care hence forms a very important framework inadvancing high-value, sustainable, and patient-centered respiratory health services inIndonesia and beyond
- 2 December 2025
- Published by Persahabatan Hospital in Persahabatan Respirology Journal
- Vol. 1 (1) , 23
Open AccessMultidiscipline in Respiratory Care
Background: Respiratory diseases continue to be one of the significant burdens of morbidityand mortality in the world, with tuberculosis, pneumonia, COPD, and lung cancer featuringamong the most important causes. These are complex conditions with comprehensivemedical, functional, nutritional, medical rehabilitation, and psychosocial managementrequirements. This narrative review outlines the rationale, structure, and clinical impact ofmultidisciplinary respiratory care and emphasizes how such care may improve outcomes,coordination, and patient satisfaction. Discussion: A multidisciplinary team that includes respirologists, thoracic surgeons, nurses,nutritionists, and palliative specialists can allow for integrated patient-centered management,with enhancement in diagnostic accuracy, treatment efficacy, and continuity of care.Evidence shows reductions in hospital readmissions, improved survival, and better quality oflife with these approaches. Persahabatan National Respiratory Hospital is an example of thisapproach through structured multidisciplinary teams in lung cancer, interstitial lung disease,and tuberculosis. Despite resource and system integration challenges, there is a promisingoutlook for strengthening digital coordination, leadership support, and national policyalignment. Conclusion: Multidisciplinary respiratory care hence forms a very important framework inadvancing high-value, sustainable, and patient-centered respiratory health services inIndonesia and beyond
- 6 June 2025
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 20 (6) , 699-702
Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Biomarker For “Cold” Tumor?
- 6 June 2025
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 20 (6) , 699-702
Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Biomarker For “Cold” Tumor?
- Open Access
- 25 March 2025
- Published by Brieflands in International Journal of Cancer Management
- Vol. 18 (1)
Real-World Analysis of Afatinib for EGFR-Mutated Lung Adenocarcinoma Under Universal Health Coverage: A Single Center Experience
Background: Afatinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), has now become standard targeted therapy for EGFR-mutated lung adenocarcinoma patients in Indonesia, and approved under universal health coverage scheme in Indonesia. Objectives: This study aimed to evaluate the outcomes and efficacy of afatinib therapy in lung adenocarcinoma patients with EGFR mutations at Persahabatan General Hospital, a tertiary referral respiratory hospital, under universal health coverage scheme. Methods: This retrospective cohort study was conducted based on medical records of EGFR-mutated lung adenocarcinoma patients who received afatinib at Thoracic Oncology Outpatient Clinic Persahabatan Hospital, between January 2018 and December 2021. All patients initially received afatinib at a dose of 40 mg dose, with some had dose reduction to 20 or 30 mg. Survival analysis was conducted using Kaplan-Meier and Log-Rank Test. Results: Among 86 participants, 78% were diagnosed with stage IVA disease at the initiation of afatinib therapy. Exon 19 deletion were observed in over 50% of patients, and pleural metastases were present in nearly 60%. The median progression-free survival (PFS) was 13 months (95% CI: 10.5 - 15.5), and the median overall survival (OS) was 17 months (95% CI: 14.9 -19.1). The one-year survival rate was 65.1%. Dose reduction occurred in 43% of participants, with no significant differences in survival outcomes. Median PFS was 15 months (95% CI: 12.4 - 17.6) with dose reduction and 12 months (95% CI: 8.1 - 15.9) without (P = 0.85). Median OS was 17 months (95% CI: 14.9 - 19.1) with dose reduction and 19 months (95% CI: 13.7 - 24.3) without (P = 0.59). Conclusions: Afatinib has comparable efficacy for EGFR-mutated lung adenocarcinoma patients and dose adjustment did not affect the survival rate, in patient under universal health coverage program in Indonesia.
- 25 March 2025
- Published by Brieflands in International Journal of Cancer Management
- Vol. 18 (1)
Open AccessReal-World Analysis of Afatinib for EGFR-Mutated Lung Adenocarcinoma Under Universal Health Coverage: A Single Center Experience
Background: Afatinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), has now become standard targeted therapy for EGFR-mutated lung adenocarcinoma patients in Indonesia, and approved under universal health coverage scheme in Indonesia. Objectives: This study aimed to evaluate the outcomes and efficacy of afatinib therapy in lung adenocarcinoma patients with EGFR mutations at Persahabatan General Hospital, a tertiary referral respiratory hospital, under universal health coverage scheme. Methods: This retrospective cohort study was conducted based on medical records of EGFR-mutated lung adenocarcinoma patients who received afatinib at Thoracic Oncology Outpatient Clinic Persahabatan Hospital, between January 2018 and December 2021. All patients initially received afatinib at a dose of 40 mg dose, with some had dose reduction to 20 or 30 mg. Survival analysis was conducted using Kaplan-Meier and Log-Rank Test. Results: Among 86 participants, 78% were diagnosed with stage IVA disease at the initiation of afatinib therapy. Exon 19 deletion were observed in over 50% of patients, and pleural metastases were present in nearly 60%. The median progression-free survival (PFS) was 13 months (95% CI: 10.5 - 15.5), and the median overall survival (OS) was 17 months (95% CI: 14.9 -19.1). The one-year survival rate was 65.1%. Dose reduction occurred in 43% of participants, with no significant differences in survival outcomes. Median PFS was 15 months (95% CI: 12.4 - 17.6) with dose reduction and 12 months (95% CI: 8.1 - 15.9) without (P = 0.85). Median OS was 17 months (95% CI: 14.9 - 19.1) with dose reduction and 19 months (95% CI: 13.7 - 24.3) without (P = 0.59). Conclusions: Afatinib has comparable efficacy for EGFR-mutated lung adenocarcinoma patients and dose adjustment did not affect the survival rate, in patient under universal health coverage program in Indonesia.
- Open Access
- 30 January 2025
- Published by Universitas Airlangga in Jurnal Respirasi
- Vol. 11 (1) , 15-21
Depression in Patients with Lung Cancer during the COVID-19 Pandemic
Introduction: The coronavirus disease (COVID-19) pandemic has caused significant disruptions in various aspects of life, leading to psychological distress and an increase in mental health disorders, particularly in vulnerable populations such as lung cancer patients. This study investigated the depression levels among lung cancer patients during the COVID-19 pandemic. Methods: A cross-sectional study was conducted at the Thoracic Oncology Outpatient Clinic of Persahabatan National Respiratory Referral Hospital, Jakarta. Depression levels were evaluated using the Patient Health Questionnaire-9 (PHQ-9) in Indonesian. Sociodemographic and clinical characteristics and COVID-19-related stress factors (such as concerns about treatment delays, access to healthcare, psychological pressure, and interpersonal relationships) were also assessed. Results: Out of 42 patients, 42.9% were found to have depression during the pandemic. Factors significantly associated with depression included being female, having a lower economic status, poor performance status, undergoing chemotherapy, and experiencing higher levels of psychological pressure related to COVID-19. Conclusion: This study highlighted a high prevalence of depression among lung cancer patients during the COVID-19 pandemic. Psychological assessment and interventions are crucial to prevent further deterioration in mental health and quality of life, which could negatively affect patients' prognoses.
- 30 January 2025
- Published by Universitas Airlangga in Jurnal Respirasi
- Vol. 11 (1) , 15-21
Open AccessDepression in Patients with Lung Cancer during the COVID-19 Pandemic
Introduction: The coronavirus disease (COVID-19) pandemic has caused significant disruptions in various aspects of life, leading to psychological distress and an increase in mental health disorders, particularly in vulnerable populations such as lung cancer patients. This study investigated the depression levels among lung cancer patients during the COVID-19 pandemic. Methods: A cross-sectional study was conducted at the Thoracic Oncology Outpatient Clinic of Persahabatan National Respiratory Referral Hospital, Jakarta. Depression levels were evaluated using the Patient Health Questionnaire-9 (PHQ-9) in Indonesian. Sociodemographic and clinical characteristics and COVID-19-related stress factors (such as concerns about treatment delays, access to healthcare, psychological pressure, and interpersonal relationships) were also assessed. Results: Out of 42 patients, 42.9% were found to have depression during the pandemic. Factors significantly associated with depression included being female, having a lower economic status, poor performance status, undergoing chemotherapy, and experiencing higher levels of psychological pressure related to COVID-19. Conclusion: This study highlighted a high prevalence of depression among lung cancer patients during the COVID-19 pandemic. Psychological assessment and interventions are crucial to prevent further deterioration in mental health and quality of life, which could negatively affect patients' prognoses.
- Open Access
- 31 October 2024
- Published by Perhimpunan Dokter Paru Indonesia in Jurnal Respirologi Indonesia
- Vol. 44 (4) , 334-339
Indonesian Society of Respirology Position Paper on Lung Cancer Control in Indonesia
Lung cancer is a major health concern in Indonesia due to its increasing prevalence, late-stage diagnosis, younger population, and high mortality. Addressing this issue requires nationwide implementation of comprehensive lung cancer control, which includes risk reduction and prevention strategies, focusing on tobacco control and air pollution mitigation. Screening with low-dose computed tomography (LDCT) and early detection in symptomatic patients, along with TB screening programs and all non-communicable diseases, is strongly recommended to enhance early case findings, treatment effectiveness, and overall patient outcomes. A multidisciplinary team (MDT) approach is important to ensure accurate diagnosis and comprehensive care. Moreover, the integration of palliative care at the early stages of advanced lung cancer is vital, focusing on symptom management and enhancing the quality of life for patients. While national guidelines are available for the diagnosis and treatment of lung cancer, significant disparities in healthcare access remain across Indonesia. Thus, it is essential to improve universal health coverage and referral systems to guarantee equal access to lung cancer care for patients at all levels through advocacy and ease of access.
- 31 October 2024
- Published by Perhimpunan Dokter Paru Indonesia in Jurnal Respirologi Indonesia
- Vol. 44 (4) , 334-339
Open AccessIndonesian Society of Respirology Position Paper on Lung Cancer Control in Indonesia
Lung cancer is a major health concern in Indonesia due to its increasing prevalence, late-stage diagnosis, younger population, and high mortality. Addressing this issue requires nationwide implementation of comprehensive lung cancer control, which includes risk reduction and prevention strategies, focusing on tobacco control and air pollution mitigation. Screening with low-dose computed tomography (LDCT) and early detection in symptomatic patients, along with TB screening programs and all non-communicable diseases, is strongly recommended to enhance early case findings, treatment effectiveness, and overall patient outcomes. A multidisciplinary team (MDT) approach is important to ensure accurate diagnosis and comprehensive care. Moreover, the integration of palliative care at the early stages of advanced lung cancer is vital, focusing on symptom management and enhancing the quality of life for patients. While national guidelines are available for the diagnosis and treatment of lung cancer, significant disparities in healthcare access remain across Indonesia. Thus, it is essential to improve universal health coverage and referral systems to guarantee equal access to lung cancer care for patients at all levels through advocacy and ease of access.
- Open Access
- 30 April 2024
- Published by Duzce Medical Journal in Düzce Tıp Fakültesi Dergisi
- Vol. 26 (1) , 88-90
Pulmonary Alveolar Proteinosis Secondary to Chronic Ethylene Oxide Occupational Inhalation
In this case report, a 40-year-old male patient with a persistent and productive cough lasting over 2 weeks, accompanied by dyspnea, who received an anti-tuberculosis drug regimen for 12 months without any clinical improvement at a different hospital before being referred to Persahabatan Central General Hospital was presented. In-depth clinical, and radiological investigations, the periodic acid-Schiff (PAS)-positive related to pulmonary alveolar proteinosis (PAP) confirmed through transbronchial biopsy (TBB). PAP is a rare lung disease with exceptionally low prevalence and incidence, Notably, the patient’s occupational environment played a crucial role in the diagnosis, as we identified occupational PAP secondary to chronic inhalation of ethylene oxide in a poorly ventilated work setting and inadequate respiratory protection. The patient was administered inhaled filgrastim (1 vial) at four intervals over 30 days, yielding favorable and satisfactory clinical as well as radiological outcomes.
- 30 April 2024
- Published by Duzce Medical Journal in Düzce Tıp Fakültesi Dergisi
- Vol. 26 (1) , 88-90
Open AccessPulmonary Alveolar Proteinosis Secondary to Chronic Ethylene Oxide Occupational Inhalation
In this case report, a 40-year-old male patient with a persistent and productive cough lasting over 2 weeks, accompanied by dyspnea, who received an anti-tuberculosis drug regimen for 12 months without any clinical improvement at a different hospital before being referred to Persahabatan Central General Hospital was presented. In-depth clinical, and radiological investigations, the periodic acid-Schiff (PAS)-positive related to pulmonary alveolar proteinosis (PAP) confirmed through transbronchial biopsy (TBB). PAP is a rare lung disease with exceptionally low prevalence and incidence, Notably, the patient’s occupational environment played a crucial role in the diagnosis, as we identified occupational PAP secondary to chronic inhalation of ethylene oxide in a poorly ventilated work setting and inadequate respiratory protection. The patient was administered inhaled filgrastim (1 vial) at four intervals over 30 days, yielding favorable and satisfactory clinical as well as radiological outcomes.
- Open Access
- 1 January 2024
- Published by Walter de Gruyter GmbH in Pneumologia
- Vol. 73 (1) , 42-46
Systemic sclerosis-related interstitial lung diseases: diagnosis and treatment approach
Interstitial lung disease (ILD) frequently occurs in systemic sclerosis (SSc), significantly increasing the mortality risk. Diagnosing ILD associated with SSc (SSc-ILD) necessitates a vigilant approach due to the absence of respiratory symptoms in some patients. Early high-resolution computed tomography (HRCT) screening for SSc diagnosis is imperative, as ILD can manifest across all SSc patients. Regular monitoring, encompassing pulmonary function tests, symptom assessment and periodic HRCT scans, is crucial for monitoring disease progression and guiding treatment strategies. Immunotherapy, typically the primary treatment for SSc-ILD, along with nintedanib, an approved antifibrotic agent, has demonstrated effectiveness in preserving lung function. Effective diagnosis and management of SSc-ILD require a comprehensive patient-centred approach aimed at optimising outcomes and enhancing quality of life.
- 1 January 2024
- Published by Walter de Gruyter GmbH in Pneumologia
- Vol. 73 (1) , 42-46
Open AccessSystemic sclerosis-related interstitial lung diseases: diagnosis and treatment approach
Interstitial lung disease (ILD) frequently occurs in systemic sclerosis (SSc), significantly increasing the mortality risk. Diagnosing ILD associated with SSc (SSc-ILD) necessitates a vigilant approach due to the absence of respiratory symptoms in some patients. Early high-resolution computed tomography (HRCT) screening for SSc diagnosis is imperative, as ILD can manifest across all SSc patients. Regular monitoring, encompassing pulmonary function tests, symptom assessment and periodic HRCT scans, is crucial for monitoring disease progression and guiding treatment strategies. Immunotherapy, typically the primary treatment for SSc-ILD, along with nintedanib, an approved antifibrotic agent, has demonstrated effectiveness in preserving lung function. Effective diagnosis and management of SSc-ILD require a comprehensive patient-centred approach aimed at optimising outcomes and enhancing quality of life.
- Open Access
- 29 September 2023
- Published by National Cancer Center Dharmais Cancer Hospital in Indonesian Journal of Cancer
- Vol. 17 (3) , 211
Three-Year Overall Survival of Advanced Stage ALK-Positive NSCLC at a Single Clinical Setting in Indonesia
Background: ALK-positive Non-Small Cell Lung Cancer (NSCLC) is a rare condition predominantly observed in much younger non-smokers with adenocarcinoma histology, often accompanied by brain metastases. Despite its unique features, there is a lack of data concerning the treatment of ALK-positive NSCLC in Indonesia. Therefore, this study represented the first attempt to document the treatment landscape for ALK-positive NSCLC in the country. The available ALK inhibitors included crizotinib, alectinib, brigatinib, and lorlatinib, and none of these were listed under the Indonesian Universal Health Coverage as of September 2022. This study aimed to characterize survival outcomes of ALK-positive NSCLC patients treated within a specialized thoracic oncology practice in Indonesia.Methods: The retrospective observational cohort study drew secondary data from medical records of ALK-positive NSCLC patients treated at a private thoracic oncology clinic. Data were collected retrospectively, spanning from December 2019 to December 31, 2022. Exclusion criteria included incomplete data, untreated ALK-positive NSCLC, cases at stage I-III, or diagnoses made after August 2021. The observation period extended up to 36 months, although several patients exceeded 48 months, with one individual currently boasting a 96-month survival.Results: A total of 15 patients with ALK-positive NSCLC were selected as the respondents in this study. The median age stood at 50.8 years, predominantly female, and diagnosed with adenocarcinoma. Predominant sites of metastasis included pleural effusion and brain metastases, and preliminary 36-month survival rates reached 73.3%. The 1-year survival rate was recorded at 100%, while the 2-year overall survival (OS) stood at 80%, aligning closely with global ALK inhibitors clinical trial data.Conclusions: This study provided the first-ever dataset indicating an ALK-positive profile within a singular thoracic oncology clinic in Indonesia. Despite the accessibility constraints of treatments, ALK-positive patients showed comparable total survival to pivotal clinical trial data. This preliminary dataset shed light on the profile and treatment of ALK-positive NSCLC in the country.
- 29 September 2023
- Published by National Cancer Center Dharmais Cancer Hospital in Indonesian Journal of Cancer
- Vol. 17 (3) , 211
Open AccessThree-Year Overall Survival of Advanced Stage ALK-Positive NSCLC at a Single Clinical Setting in Indonesia
Background: ALK-positive Non-Small Cell Lung Cancer (NSCLC) is a rare condition predominantly observed in much younger non-smokers with adenocarcinoma histology, often accompanied by brain metastases. Despite its unique features, there is a lack of data concerning the treatment of ALK-positive NSCLC in Indonesia. Therefore, this study represented the first attempt to document the treatment landscape for ALK-positive NSCLC in the country. The available ALK inhibitors included crizotinib, alectinib, brigatinib, and lorlatinib, and none of these were listed under the Indonesian Universal Health Coverage as of September 2022. This study aimed to characterize survival outcomes of ALK-positive NSCLC patients treated within a specialized thoracic oncology practice in Indonesia.Methods: The retrospective observational cohort study drew secondary data from medical records of ALK-positive NSCLC patients treated at a private thoracic oncology clinic. Data were collected retrospectively, spanning from December 2019 to December 31, 2022. Exclusion criteria included incomplete data, untreated ALK-positive NSCLC, cases at stage I-III, or diagnoses made after August 2021. The observation period extended up to 36 months, although several patients exceeded 48 months, with one individual currently boasting a 96-month survival.Results: A total of 15 patients with ALK-positive NSCLC were selected as the respondents in this study. The median age stood at 50.8 years, predominantly female, and diagnosed with adenocarcinoma. Predominant sites of metastasis included pleural effusion and brain metastases, and preliminary 36-month survival rates reached 73.3%. The 1-year survival rate was recorded at 100%, while the 2-year overall survival (OS) stood at 80%, aligning closely with global ALK inhibitors clinical trial data.Conclusions: This study provided the first-ever dataset indicating an ALK-positive profile within a singular thoracic oncology clinic in Indonesia. Despite the accessibility constraints of treatments, ALK-positive patients showed comparable total survival to pivotal clinical trial data. This preliminary dataset shed light on the profile and treatment of ALK-positive NSCLC in the country.
- Open Access
- 31 May 2023
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 17 (05) , 617-622
Severe acute respiratory syndrome coronavirus-2 antibody response after Moderna vaccine booster on healthcare providers
Introduction: As an endeavor to control SARS-CoV-2 infection, the Moderna vaccine booster was given to healthcare workers to prevent reinfection and reduce the risk of complications from COVID-19. A heterologous booster vaccine is also thought to provide better protection against the current SARS-CoV-2 variants of concern. However, research that evaluates the effectiveness of the Moderna vaccine booster and the resulting SARS-CoV-2 antibody concentration is needed. Objective: To evaluate the concentration of SARS-CoV-2 antibodies after the Moderna vaccine booster and the severity of SARS-CoV-2 infection before and after the Moderna vaccine booster. Results: A total of 93 healthcare providers who received Moderna vaccine booster were included in the study. Examination of antibody concentration 3 months after the booster showed an average concentration of 10081.65 U/mL. There was an increase in antibody concentration before the booster and 3 months after, from a median of 1.7 U/mL to 9540 U/mL. Every subject showed a statistically significant increment of antibody concentration 3 months after the booster (p < 0.01). Thirty-seven (39.8%) subjects received two doses of the Sinovac vaccine and were confirmed to have COVID-19 with the Delta variant. After the booster, 26 (28%) subjects were infected with the Omicron Variant. Among the subjects who received two doses of the Sinovac vaccine and were confirmed with COVID-19, 36 (30.1%) had mild symptoms, and 1 (1.1%) was asymptomatic. Conclusions: Heterologous Moderna vaccine booster effectively increases antibody response against SARS-CoV-2 variants and shows mild symptoms of COVID-19 infection.
- 31 May 2023
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 17 (05) , 617-622
Open AccessSevere acute respiratory syndrome coronavirus-2 antibody response after Moderna vaccine booster on healthcare providers
Introduction: As an endeavor to control SARS-CoV-2 infection, the Moderna vaccine booster was given to healthcare workers to prevent reinfection and reduce the risk of complications from COVID-19. A heterologous booster vaccine is also thought to provide better protection against the current SARS-CoV-2 variants of concern. However, research that evaluates the effectiveness of the Moderna vaccine booster and the resulting SARS-CoV-2 antibody concentration is needed. Objective: To evaluate the concentration of SARS-CoV-2 antibodies after the Moderna vaccine booster and the severity of SARS-CoV-2 infection before and after the Moderna vaccine booster. Results: A total of 93 healthcare providers who received Moderna vaccine booster were included in the study. Examination of antibody concentration 3 months after the booster showed an average concentration of 10081.65 U/mL. There was an increase in antibody concentration before the booster and 3 months after, from a median of 1.7 U/mL to 9540 U/mL. Every subject showed a statistically significant increment of antibody concentration 3 months after the booster (p < 0.01). Thirty-seven (39.8%) subjects received two doses of the Sinovac vaccine and were confirmed to have COVID-19 with the Delta variant. After the booster, 26 (28%) subjects were infected with the Omicron Variant. Among the subjects who received two doses of the Sinovac vaccine and were confirmed with COVID-19, 36 (30.1%) had mild symptoms, and 1 (1.1%) was asymptomatic. Conclusions: Heterologous Moderna vaccine booster effectively increases antibody response against SARS-CoV-2 variants and shows mild symptoms of COVID-19 infection.
- Open Access
- 16 April 2023
- Published by Perhimpunan Dokter Paru Indonesia in Jurnal Respirologi Indonesia
- Vol. 43 (2) , 144-150
Indonesian Society of Respirology (ISR) Consensus Statement on Lung Cancer Screening and Early Detection in Indonesia
Lung cancer is the leading cause of mortality for all cancer globally and in Indonesia. In Indonesia, lung cancer contributes to 12.6% of death of all cancer, making it the number one cause of cancer death, and 8.6% of all cancer incidence in 2018, behind breast, cervical, and colorectal cancer. The total cases per year are expected to almost double from 30,023 in 2018 to 54,983 cases in 2040. Smoking is among the risk factors for lung cancer, after occupational/environmental risk factors, history of lung fibrosis, and family history of cancer. There was a tendency of younger smokers in Indonesia and increased lung cancer incidence and prevalence in the younger population. The median age of lung cancer in Indonesia was younger than in any country, probably due to the younger age of smoking, early onset of carcinogens, asbestos use, and environmental. Lung cancer screening is a voluntary measure to detect lung cancer in the earliest stage, to find cancer at curable disease before symptoms appear in high-risk individuals. Lung cancer early detection is strategies to find cancer earlier after symptoms appear (cough, hemoptysis, dyspnea, chest pain). Low-dose computerized tomography of the thorax (LDCT) screening has been known to reduce lung cancer mortality compared to a chest x-ray (CXR). This Indonesian Society of Respirology consensus statement was aimed to give recommendations on lung cancer screening and early diagnosis in Indonesia.
- 16 April 2023
- Published by Perhimpunan Dokter Paru Indonesia in Jurnal Respirologi Indonesia
- Vol. 43 (2) , 144-150
Open AccessIndonesian Society of Respirology (ISR) Consensus Statement on Lung Cancer Screening and Early Detection in Indonesia
Lung cancer is the leading cause of mortality for all cancer globally and in Indonesia. In Indonesia, lung cancer contributes to 12.6% of death of all cancer, making it the number one cause of cancer death, and 8.6% of all cancer incidence in 2018, behind breast, cervical, and colorectal cancer. The total cases per year are expected to almost double from 30,023 in 2018 to 54,983 cases in 2040. Smoking is among the risk factors for lung cancer, after occupational/environmental risk factors, history of lung fibrosis, and family history of cancer. There was a tendency of younger smokers in Indonesia and increased lung cancer incidence and prevalence in the younger population. The median age of lung cancer in Indonesia was younger than in any country, probably due to the younger age of smoking, early onset of carcinogens, asbestos use, and environmental. Lung cancer screening is a voluntary measure to detect lung cancer in the earliest stage, to find cancer at curable disease before symptoms appear in high-risk individuals. Lung cancer early detection is strategies to find cancer earlier after symptoms appear (cough, hemoptysis, dyspnea, chest pain). Low-dose computerized tomography of the thorax (LDCT) screening has been known to reduce lung cancer mortality compared to a chest x-ray (CXR). This Indonesian Society of Respirology consensus statement was aimed to give recommendations on lung cancer screening and early diagnosis in Indonesia.